Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Boceprevir triple therapy in treatment-naive genotype 1 chronic hepatitis C
2011-004810-41Phase 3Completed
- Sponsor
- Roche
- Start
- Feb 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of boceprevir in hepatitis C virus infection, sponsored by Roche. Primary endpoint: Sustained virological response rate. Started Feb 2012; status: completed.
02
Drugs
boceprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2011-004810-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004810-41.